LABORATOIRE X.O
Acquired by
STANLEY CAPITAL PARTNERS
LABORATOIRE X.O acquired by STANLEY CAPITAL PARTNERS
Target
LABORATOIRE X.O
Acquirer
STANLEY CAPITAL PARTNERS
Context
Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG). This new phase focuses on a strategic merger with Noden Pharma (another SCP portfolio company), providing X.O with a commercial platform in Ireland and the United States. The goal remains to triple revenue within 3-4 years through aggressive portfolio acquisitions.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 2015, Laboratoire X.O is a specialty pharmaceutical company focused on acquiring and revitalizing mature drug brands (Legacy Brands) from "Big Pharma." It operates an asset-light model, outsourcing production while managing 21 Market Authorizations (MA). Its portfolio includes prescription drugs and a growing Over-The-Counter (OTC) division, with key brands like Prexidine (mouthwash).
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with LABORATOIRE X.O
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 11/2020 | NOVALPINA CAPITAL | LABORATOIRE X.O | FRANCE | Generics / Labs | Novalpina Capital made its first French investment by acquiring a controlling stake in Laboratoire X.O. The deal values the company at over EUR300M, supported by a unitranche debt facility from Ares Management. Novalpina has also reserved EUR100M for future acquisitions. The objective is to triple revenue within five years by acquiring more drug portfolios and expanding the group's international footprint beyond France and Francophone Africa. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.